Generic placeholder image

Current Respiratory Medicine Reviews


ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Research Article

Risk Factors for In-Hospital Mortality among Cancer Patients with COVID-19: A Cross-Sectional Study

Author(s): Iman Ghasemzadeh, Masoud Mardani, Nasrinsadat Mirtalaee, Ghazal Sanadgol and Sara Abolghasemi*

Volume 18, Issue 1, 2022

Published on: 02 March, 2022

Page: [57 - 64] Pages: 8

DOI: 10.2174/1573398X18666220208102258

Price: $65


Background: COVID-19 has been a major concern for people and healthcare systems since its emergence in China in December 2019. Patients with medical diseases are at a higher risk of severe disease development and mortality. Cancer patients are more vulnerable to infections. Several studies demonstrated that COVID-19 is associated with a greater risk of morbidity and mortality among cancer patients. However, the risk factors for mortality among these patients are still unknown.

Objective: This study aimed to identify the risk factors associated with in-hospital death among cancer patients with COVID-19.

Methods: In this cross-sectional study, we analyzed demographic data, clinical characteristics and laboratory parameters of cancer patients with COVID-19 who were hospitalized in three tertiary referral hospitals in Tehran, Iran from February to May 2020. Diagnosis of COVID-19 was confirmed using real-time polymerase chain reaction testing and computed tomography scan findings. Data analysis was performed using SPSS software, version 20. P-value less than 0.05 was considered significant.

Results: Sixty-six cancer patients with COVID-19 were enrolled in this study. Among participants, 35 (53.03%) patients were discharged, and 31 (46.97%) patients died in the hospital. Thirty-two (48.4%) patients suffered from hematologic and 34 (51.6%) from non-hematologic cancers. The most common comorbidities were hypertension (68.18%) and diabetes (56.06%). The most common symptoms among patients were rhinorrhea (59.1%), fever (54.5%), and dyspnea (48.4%), respectively. Diabetes (p= 0.00), hypoxemia (p= 0.005), and receiving chemotherapy or radiotherapy during the last three months (p= 0.022) were associated with a significantly greater risk of in-hospital mortality.

Conclusion: Hypoxemia, diabetes, and the time interval between chemotherapy/radiotherapy and hospitalization are associated with a higher risk of in-hospital mortality among cancer patients with COVID-19. These risk factors should be considered in the clinical management of hospitalized COVID19 patients who suffer from cancers. In-hospital mortality and poor outcomes can be minimized by addressing risk factors.

Keywords: Mortality, cancer, covid-19, coronavirus, death, risk factor.

Motlagh A, Yamrali M, Azghandi S, et al. COVID19 prevention & care; a cancer specific guideline. Arch Iran Med 2020; 23(4): 255-64.
[] [PMID: 32271599]
Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020; 109: 102434.
[] [PMID: 32143990]
Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69(4): 635-64.
[] [PMID: 16339739]
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324(8): 782-93.
[] [PMID: 32648899]
Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362(9380): 263-70.
[] [PMID: 12892955]
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367(19): 1814-20.
[] [PMID: 23075143]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
[] [PMID: 32085846]
Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three-month experience. MedRxiv 2020.
Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19 infection. Clin Infect Dis 2020.
Haghighat S, Dehghani M. COVID-19 in immunosuppressed and cancer patients: A review. Asian Paci Cancer Care 2020; 5(S1): 69-73.
Mohamed-Ahmed O, McDonald B, Pardinaz-Solis R, et al. The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) response to the Zika virus outbreak. F1000 Res 2016; 5.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[] [PMID: 31986264]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[] [PMID: 32031570]
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475-81.
[] [PMID: 32105632]
Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003; 58(8): 686-9.
[] [PMID: 12885985]
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020; 21(3): 335-7.
[] [PMID: 32066541]
Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020; 10(7): 935-41.
[] [PMID: 32357994]
Arabi YM, Balkhy HH, Hayden FG, et al. Middle East respiratory syndrome. N Engl J Med 2017; 376(6): 584-94.
[] [PMID: 28177862]
Gandhi RT, Lynch JB, Del Rio C. Mild or moderate COVID-19. N Engl J Med 2020; 383(18): 1757-66.
[] [PMID: 32329974]
Assaad S, Avrillon V, Fournier M-L, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. Eur J Cancer 2020; 135: 251-9.
[] [PMID: 32540204]
Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet 2020; 395(10241): 1919-26.
[] [PMID: 32473682]
Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer 2020; 139: 43-50.
[] [PMID: 32971510]
de Azambuja E, Brandão M, Wildiers H, et al. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: A nationwide, population-based analysis. ESMO Open 2020; 5(5): e000947.
[] [PMID: 32978251]
Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol 2020; 21(7): 904-13.
[] [PMID: 32479787]
Lee LYW, Cazier J-B, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: A prospective cohort study. Lancet Oncol 2020; 21(10): 1309-16.
[] [PMID: 32853557]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy